GLP-1 and its structurally-related synthetic peptides (e.g., exenatide, liraglutide) lower levels of blood glucose in patients with T2DM while also suppressing appetite in some of these patients5,6,21–23. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.